Effect of an Antiinflammatory Diet on Postprandial Gene Expression of Mononuclear Cells of Adult Obese Women

June 8, 2021 updated by: Diana M Munoz, Universidad de Caldas
Obesity is one of the major health problems worldwide. The consumption of healthy-dietary patterns can be difficult in some countries due to the availability of certain foods. Suggestion of alternative foods could be a necessity. The purpose of this study was to evaluate the effect of a dietary pattern consisting of fruit, avocado, whole-grains and trout (FAWGT) on postprandial gene expression, insulinemia and lipemia in Colombian obese people.

Study Overview

Status

Completed

Conditions

Detailed Description

A randomized controlled crossover study was conducted. Volunteers underwent to two dietary models for 8 weeks each, including a 2 weeks washout diet between them. The order in which they started the interventions was randomized following a computerized assignment list using Excel software (Microsoft Office 2015, Excel 2013).

The primary endpoint was the postprandial gene expression of nuclear factor kappa B subunit 1 (NFKB1) gene. Based on previous studies , 20 individuals had to be studied to detect a 0.2 difference in the expression of the NKKB1 gene between diets with 0.05 significance level and 80 percentage power (type II error Z 0.2), assuming a 10 percentage drop-out rate.

The recruitment of participants was carried out according to the following steps:

  1. Review of clinical histories of patients diagnosed with obesity, according to their Body Mass Index, ascribed to the chronic non-communicable diseases program of the Clinica Comfamiliar Risaralda in the city of Pereira Colombia.
  2. Telephone call to invite the participants who met the inclusion criteria to participate in the study.
  3. Appointment prior to the start of the study to take a blood sample to corroborate the inclusion criteria. With this sample the following tests were performed: blood glucose, lipid profile, thyroid stimulating hormone (TSH), C-reactive protein ( and complete blood count.

This process was carried out by personnel not involved in the research. The results obtained were compared with the clinical history.

The diets followed during the intervention periods were: (1) a diet consisting mainly of the consumption of fruit, avocado and other vegetables, whole grains and trout typical of the colombian coffee region (FAWGT) (experimental diet), and (2) the usual diet consumed by the participants in their normal lifestyle (UD).

At the beginning of the dietary intervention period, each participant was given an individualized food guide containing the suggested food group and portions, with a wide variety of foods allowed for greater adherence to the diet. In addition, specific times for consumption of the foods and precise instructions for the dietary intervention were given. In addition, the subjects were given a talk advising them how to quantify the portions, which would later be converted into grams according to the procedure described

The food portions were standardized with all the participants using synthetic models, adapted according to the Colombian nutritional guidelines, so that they could provide a more accurate report of the portions consumed during the intervention. In addition, a postprandial studies were carried out at the beginning of the study (pre-intervention) and another after 8 weeks of dietary intervention (post-intervention).

The participants were given an appointment at the health center at 7.00 am, after at least 12 hours of fasting and a 5 day abstinence from alcohol. They consumed a breakfast based on the same composition of the diet in which they were randomized for the dietary intervention period. The blood samples were obtained by veni-puncture at baseline and 4 hours after breakfast. During the postprandial period, the participants did not consume any more food, although they were allowed to drink water. The breakfasts were composed of the following foods: FAWGT diet; whole-grain arepa (with unrefined corn flour), cheese, oats, granadilla, mango, linseed, nuts, almonds, peanuts and yogurt. Usual diet; egg, cheese, butter, whole milk, traditional white arepa (with re-fined corn flour), traditional buñuelo (made from wheat flour with cheese), coffee and sugar.

Before starting the dietary intervention period (Pre-intervention), at the midpoint of the study (week 4) and at the end (week 8), all the participants completed three 24-hour recalls (2 non-consecutive weekdays and one weekend day) to obtain information about food, ingredients and preparations consumed in the same units of measurement (grams).

In addition, a weekly telephone call was made to answer any questions relating to the diet (recipes, menu and quantities) and to motivate adherence to the assigned dietary model.

Moreover, in week four of each intervention, the participants attended the hospital for an interview with the main researcher in order to take anthropometric measurements, evaluate the follow-up of the dietary instructions and answer any questions that may have arisen during the intervention, and motivate them to continue with the study. To collect the information on food consumption, formats and questionnaires previously published by the research group were used.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Risaralda
      • Pereira, Risaralda, Colombia, 16000
        • Clínica Comfamiliar Risaralda

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed consent
  • Body mass index (BMI) ≥ 30 Kg/m^2.
  • Clinical: hypertensive and dyslipidemic participants.

Exclusion Criteria:

  • Age < 40 or > 65 years
  • Patients unable to follow a protocol.
  • Psychiatric diseases
  • Renal Insufficiency
  • Chronic Hepatopathy
  • Active Malignancy
  • Chronic obstructive pulmonary disease
  • Diseases of the digestive tract Endocrine disorders
  • Smokers.
  • Regular alcohol consumers.
  • Participants who were in weight reduction programs
  • Prescribed hypolipidaemic medication
  • Prescribed anti-inflammatory medication
  • Kidney or liver dysfunction.
  • Diabetes or other endocrine disorders.
  • Chronic inflammatory conditions.
  • Patients participating in other Clinical trials (in the enrollment moment or 30 days prior).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FAWGT Diet
Composed of fruit, avocado, whole grains and trout
Composed of 15% protein, 55% CH and 30% fat of which < 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
Active Comparator: Usual diet (UD)
Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relative expression of the NFKB1 gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification in fasting and postprandial state.
8 weeks
Relative expression of the Interleukin 6 (IL6) gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification in fasting and postprandial state.
8 weeks
Relative expression of the tumoral necrosis factor (TNF) gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification in fasting and postprandial state.
8 weeks
Relative expression of the Interleukin 1 B (IL1B) gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification in fasting and postprandial state..
8 weeks
Relative expression of the matrix metallopeptidase 9 (MMP)) gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification in fasting and postprandial state.
8 weeks
Relative expression of the nuclear factor, erythroid 2 like 2 (NFE2L2) gene
Time Frame: 8 weeks
RNA extraction from mononuclear cells, reverse transcription and DNA amplification.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline of the gut microbiota
Time Frame: 8 weeks
Stool deoxyribonucleic acid (DNA) extraction, library construction, sequencing and bioinformatic analysis.
8 weeks
Change from baseline of DNA methylation pattern
Time Frame: 8 weeks
Whole blood DNA extraction and Enzyme-Linked ImmunoSorbent Assay (ELISA)
8 weeks
Triglycerides
Time Frame: 8 weeks
Influence of diet on postprandial trygliceride
8 weeks
Insulin
Time Frame: 8 weeks
Influence of diet on postprandial insulinemia
8 weeks
Total Cholesterol
Time Frame: 8 weeks
Influence of diet on postprandial total Cholesterol
8 weeks
LDL Cholesterol
Time Frame: 8 weeks
Influence of diet on postprandial LDL Cholesterol
8 weeks
HDL Cholesterol
Time Frame: 8 weeks
Influence of diet on postprandial HDL Cholesterol
8 weeks
VLDL Cholesterol
Time Frame: 8 weeks
Influence of diet on postprandial VLDL Cholesterol
8 weeks
C-reactive protein (CRP)
Time Frame: 8 weeks
Influence of diet on postprandial CRP
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Clara H Gonzalez Correa, Doctor, Universidad de Caldas
  • Principal Investigator: Diana M Muñoz, PhD student, Universidad de Caldas
  • Principal Investigator: Oriol A Rangel Zuñiga, Postdoctor, Instituto Maimónides de Investigación Biomédica de Córdoba
  • Principal Investigator: Antonio Camargo, Postdoctor, Instituto Maimónides de Investigación Biomédica de Córdoba
  • Study Chair: Elcy Y Astudillo Muñoz, Doctor, Universidad Libre
  • Study Chair: Gloria L Porras Hurtado, Postdoctor, Clínica Comfamiliar Risaralda
  • Study Chair: Maite Sanchez Giraldo, PhD student, Instituto Maimónides de Investigación Biomédica de Córdoba

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 6, 2018

Primary Completion (Actual)

June 18, 2018

Study Completion (Actual)

June 18, 2018

Study Registration Dates

First Submitted

May 25, 2021

First Submitted That Met QC Criteria

June 8, 2021

First Posted (Actual)

June 9, 2021

Study Record Updates

Last Update Posted (Actual)

June 9, 2021

Last Update Submitted That Met QC Criteria

June 8, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on FAWGT diet

Subscribe